Moreover, Xiaolin Zhu et al. [28] identified that USP11 promotes carboplatin-chemoresistance in ovarian cancer by stabilizing BIP dependent on its catalytic activity, and USP11 non-specific inhibitor mitoxantrone effectively increases the sensitivity of ovarian cancer to carboplatin chemotherapy. Here, USP11 is linked to ovarian carcinoma.